There remains an active debate within the psychedelic community about the importance of psychedelic experiences to these drugs’ therapeutic effects. Delix Therapeutics is developing compounds, called psychoplastogens, that act similarly to psychedelic compounds at the molecular level but do not induce hallucinations. We spoke with the Delix team to find out more about their research's progress.